Sciegen Pharmaceuticals Inc (United States) has no DMF, CEP or site registration linked in our records. 13 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Sciegen Pharmaceuticals Inc: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/sciegen-pharmaceuticals-inc

Overview

Sciegen Pharmaceuticals Inc is a pharmaceutical company headquartered in Hauppauge, United States.

FDA compliance signals

13 FDA enforcement records linked to this company.

  • 4832026-05-15

    SOPs not followed / documented

  • 4832026-05-15

    Sanitation--buildings not clean, free of infestation

  • recall — Class III2023-03-08

    Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.

  • 4832019-06-21

    Absence of Written Procedures

  • 4832019-06-21

    Complete instructions, procedures, specifications et. al.

  • 4832019-06-21

    Investigations of discrepancies, failures

  • recall — Class II2018-11-28

    CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

  • recall — Class II2018-11-28

    CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

  • recall — Class II2018-11-28

    CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

  • recall — Class II2018-11-28

    CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

  • recall — Class II2018-11-28

    CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

  • recall — Class II2018-11-28

    CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

  • 4832015-01-09

    Procedures not in writing, fully followed

For suppliers

Is this Sciegen Pharmaceuticals Inc?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.